Public-data analysis links low HDAC6 expression to poorer survival in hepatocellular carcinoma
Background: Connecting the cytoskeleton with tumor signaling
An integrated analysis of public hepatocellular carcinoma data found that low HDAC6 expression was associated with poorer survival. The researchers proposed a possible regulatory axis connecting the cytoskeleton, Wnt signaling, and immune regulation. Because this is a hypothesis derived from bioinformatics analyses, it should not be interpreted as experimental proof that modulating HDAC6 suppresses cancer-cell metastasis.
Hepatocellular carcinoma is difficult to treat because its molecular features vary and it is often diagnosed late. This study focused on the relationship between cytoskeletal changes, epigenetic regulation, and tumor signaling. Histone deacetylase 6 (HDAC6) regulates the acetylation of cytoplasmic proteins and is involved in alpha-tubulin stability. Beta-catenin, encoded by CTNNB1, is a key component of Wnt signaling. However, whether HDAC6, TUBA1A, and CTNNB1 form a connected regulatory axis in hepatocellular carcinoma, and what functional significance it might have, remained unclear.
Key findings: Associations in expression, survival, and immune infiltration
The researchers used public datasets and analysis platforms, including The Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA). They examined gene expression, promoter methylation, associations with survival, immune-cell infiltration, regulatory RNA interactions, and potential as therapeutic targets.
HDAC6 expression was significantly lower in hepatocellular carcinoma tissue, while TUBA1A and CTNNB1 expression was higher. Low HDAC6 expression was associated with poorer survival, but TUBA1A and CTNNB1 showed no significant prognostic value. The expression differences therefore do not mean that all three genes have the same significance as prognostic markers.
Methylation patterns also differed by gene. Hypomethylation was reported for CTNNB1, while differential methylation patterns were reported for HDAC6 and TUBA1A. In the immune-infiltration analysis, HDAC6 expression was positively correlated with cytotoxic immune-cell populations and negatively correlated with immunosuppressive cell populations. These results alone do not establish that HDAC6 directly alters immune-cell composition.
Regulatory-network analysis proposed interactions among long non-coding RNA (lncRNA), microRNA (miRNA), and messenger RNA (mRNA) involving SNHG1. In silico assessment of CRISPR targeting potential and transcriptome analysis of extracellular vesicles (EVs) were also included in the exploration of possible applications of the regulatory axis. This does not mean that actual gene-editing effects or EV-based diagnostic performance were validated.
Meaning and outlook: A hypothesis to test before establishing mechanism
Taken together, the researchers proposed that the HDAC6–alpha-tubulin–beta-catenin regulatory axis may be altered in hepatocellular carcinoma. The findings provide a basis for follow-up studies of the links among cytoskeletal remodeling, tumor signaling, and immune regulation. However, the observed associations cannot establish the order of interactions among the three molecules or a causal relationship with cancer progression.
The available abstract did not provide the sample size, detailed definitions of survival endpoints, effect sizes, or conditions used to adjust the analyses. It is therefore difficult to quantify the strength of the prognostic association or its clinical utility. The researchers also stated that further experimental validation is needed to develop these findings into biomarkers or therapeutic-target candidates. There is also insufficient evidence to interpret the association between low HDAC6 expression and poorer survival as a conclusion about the therapeutic effect of HDAC6 inhibitors.
The study is described in the abstract and bibliographic record for the International Journal of Molecular Sciences paper.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, characterized by marked molecular heterogeneity, late-stage diagnosis, and limited therapeutic options. Emerging evidence highlights the interplay between cytoskeletal dynamics, epigenetic regulation, and oncogenic signaling pathways in hepatocarcinogenesis. Histone deacetylase 6 (HDAC6), a key regulator of cytoplasmic protein acetylation, modulates α-tubulin stability, while CTNNB1 (β-catenin) serves as a central effector of the Wnt signaling pathway. However, the existence and functional relevance of a coordinated HDAC6-TUBA1A-CTNNB1 regulatory axis in HCC remain insufficiently explored. We conducted a comprehensive integrative bioinformatic analysis using multiple publicly available datasets and platforms, including TCGA, GEO, GEPIA3, TNMplot, UALCAN, TIMER2.0, STRING, ENCORI, HPA, TargetScan, miRDB, CRISPRdb, GSCALite, and exoRBase. Gene expression, promoter methylation, survival associations, immune infiltration, regulatory RNA interactions, and therapeutic targetability were systematically evaluated. HDAC6 expression was significantly downregulated in HCC tissues, whereas TUBA1A and CTNNB1 were upregulated. Reduced HDAC6 expression was associated with poorer survival outcomes, while TUBA1A and CTNNB1 showed no significant prognostic value. Methylation analysis revealed gene-specific epigenetic alterations, including hypomethylation of CTNNB1 and differential methylation patterns in HDAC6 and TUBA1A. Immune infiltration analysis demonstrated that HDAC6 expression positively correlated with cytotoxic immune cell populations and negatively with immunosuppressive subsets. Regulatory network analyses identified lncRNA-miRNA-mRNA interactions, particularly involving SNHG1. Furthermore, in silico CRISPR targetability and extracellular vesicle (EV) transcript profiling suggested potential translational applicability of this axis. Our findings support a hypothesis of the exist
This study could provide a starting point for follow-up evaluation of biomarkers and therapeutic-target candidates in hepatocellular carcinoma. For example, researchers could test whether the association between HDAC6 expression and survival is reproduced in an independent patient cohort, and whether modulating HDAC6 in cell and animal models changes cytoskeletal, Wnt-signaling, and immune-related features together. These are questions for future research, not validations completed by this study. The current results do not provide enough evidence to select a treatment for a patient or assess the benefits and risks of HDAC6 inhibitors. Neither early-diagnosis performance nor a survival benefit has been demonstrated.